Cargando…

Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study

BACKGROUND: This study aimed to assess the long-term effectiveness of the 0.2 μg/day fluocinolone acetonide (FAc) implant over ≥3 years for patients with diabetic macular oedema. METHODS: A retrospective audit of pseudo-anonymised data from patients with chronic diabetic macular oedema (cDMO) and tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, Clare, Chakravarthy, Usha, Lotery, Andrew, Menon, Geeta, Talks, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107780/
https://www.ncbi.nlm.nih.gov/pubmed/33972705
http://dx.doi.org/10.1038/s41433-021-01542-w
_version_ 1783690013061414912
author Bailey, Clare
Chakravarthy, Usha
Lotery, Andrew
Menon, Geeta
Talks, James
author_facet Bailey, Clare
Chakravarthy, Usha
Lotery, Andrew
Menon, Geeta
Talks, James
author_sort Bailey, Clare
collection PubMed
description BACKGROUND: This study aimed to assess the long-term effectiveness of the 0.2 μg/day fluocinolone acetonide (FAc) implant over ≥3 years for patients with diabetic macular oedema. METHODS: A retrospective audit of pseudo-anonymised data from patients with chronic diabetic macular oedema (cDMO) and treated with the FAc implant across 14 UK clinical sites. Safety and clinical effectiveness were measured. RESULTS: Two-hundred and fifty-six eyes had ≥3 years of follow-up (mean 4.28 years), during which a mean of 1.14 FAc implants were used per eye. Mean best-recorded visual acuity (BRVA) increased from 52.6 to 56.7 letters at month 3 and remained stable thereafter; this trend was also seen in pseudophakic eyes. The proportion of patients attaining a BRVA ≥6/12 increased from 17% at baseline to 27% 1 month after FAc implant and remained stable above 30% from month 12 onwards. Eyes with no prior history of intraocular pressure (IOP)-related events required significantly less treatment-emergent IOP-lowering medication than those with a prior history of IOP events (17.9% vs. 50.0% of eyes; p < 0.001). The incidence of an IOP increase of ≥10 mmHg, use of IOP-lowering medication, laser trabeculoplasty and IOP-lowering surgery was 28.9%, 29.7%, 0.8% and 2.7%, respectively, for the whole cohort. There were significant reductions in mean central foveal thickness and macular volume (p < 0.001). CONCLUSIONS: The FAc implant was well tolerated, with predictable and manageable IOP-related events while delivering a continuous microdose of corticosteroid to eyes with cDMO, providing prolonged vision preservation and a reduced number of treatments.
format Online
Article
Text
id pubmed-8107780
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-81077802021-05-10 Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study Bailey, Clare Chakravarthy, Usha Lotery, Andrew Menon, Geeta Talks, James Eye (Lond) Article BACKGROUND: This study aimed to assess the long-term effectiveness of the 0.2 μg/day fluocinolone acetonide (FAc) implant over ≥3 years for patients with diabetic macular oedema. METHODS: A retrospective audit of pseudo-anonymised data from patients with chronic diabetic macular oedema (cDMO) and treated with the FAc implant across 14 UK clinical sites. Safety and clinical effectiveness were measured. RESULTS: Two-hundred and fifty-six eyes had ≥3 years of follow-up (mean 4.28 years), during which a mean of 1.14 FAc implants were used per eye. Mean best-recorded visual acuity (BRVA) increased from 52.6 to 56.7 letters at month 3 and remained stable thereafter; this trend was also seen in pseudophakic eyes. The proportion of patients attaining a BRVA ≥6/12 increased from 17% at baseline to 27% 1 month after FAc implant and remained stable above 30% from month 12 onwards. Eyes with no prior history of intraocular pressure (IOP)-related events required significantly less treatment-emergent IOP-lowering medication than those with a prior history of IOP events (17.9% vs. 50.0% of eyes; p < 0.001). The incidence of an IOP increase of ≥10 mmHg, use of IOP-lowering medication, laser trabeculoplasty and IOP-lowering surgery was 28.9%, 29.7%, 0.8% and 2.7%, respectively, for the whole cohort. There were significant reductions in mean central foveal thickness and macular volume (p < 0.001). CONCLUSIONS: The FAc implant was well tolerated, with predictable and manageable IOP-related events while delivering a continuous microdose of corticosteroid to eyes with cDMO, providing prolonged vision preservation and a reduced number of treatments. Nature Publishing Group UK 2021-05-10 2022-05 /pmc/articles/PMC8107780/ /pubmed/33972705 http://dx.doi.org/10.1038/s41433-021-01542-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Bailey, Clare
Chakravarthy, Usha
Lotery, Andrew
Menon, Geeta
Talks, James
Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study
title Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study
title_full Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study
title_fullStr Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study
title_full_unstemmed Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study
title_short Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study
title_sort extended real-world experience with the iluvien® (fluocinolone acetonide) implant in the united kingdom: 3-year results from the medisoft® audit study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107780/
https://www.ncbi.nlm.nih.gov/pubmed/33972705
http://dx.doi.org/10.1038/s41433-021-01542-w
work_keys_str_mv AT baileyclare extendedrealworldexperiencewiththeiluvienfluocinoloneacetonideimplantintheunitedkingdom3yearresultsfromthemedisoftauditstudy
AT chakravarthyusha extendedrealworldexperiencewiththeiluvienfluocinoloneacetonideimplantintheunitedkingdom3yearresultsfromthemedisoftauditstudy
AT loteryandrew extendedrealworldexperiencewiththeiluvienfluocinoloneacetonideimplantintheunitedkingdom3yearresultsfromthemedisoftauditstudy
AT menongeeta extendedrealworldexperiencewiththeiluvienfluocinoloneacetonideimplantintheunitedkingdom3yearresultsfromthemedisoftauditstudy
AT talksjames extendedrealworldexperiencewiththeiluvienfluocinoloneacetonideimplantintheunitedkingdom3yearresultsfromthemedisoftauditstudy
AT extendedrealworldexperiencewiththeiluvienfluocinoloneacetonideimplantintheunitedkingdom3yearresultsfromthemedisoftauditstudy